1Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes[J]. J Am Coll Cardiol, 2005, 46(8): 1425-1433.
3Ongini E, Impagnatiello F, Bonazzi A, et al. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties[J]. Proc Natl Acad Sci USA, 2004, 101(22): 8497 - 8502.
4Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide[J]. CircRes. 2002, 90(1) : 21-28.
5Serajuddin ATM, Ranadive SA, Mahoney EM. Relative lipophilicities, solubilities, and structure pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitors pravastatin,lovastatin, mevastatin, and simvastatin[J]. J Pharmacol Sci, 1991, 80(9): 830-834.
6Carini M, Aldini G, Stefani R, et al. Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy [J]. J Pharmacol Biomed Anal, 2001, 26(4) :509-518.
7Wallace JL, Ignarro LJ, Fiorucci S. Potential cardioprotective actions of no-releasing aspirin [J]. Nat Rev Drug Discov, 2002, 1:375-382.
8Negre-Aminou P, Van Vliet AK, Van Erck M, et al.Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: Comparison with other human cell types [J]. Biochim Biophys Acta,1997, 1345(3) :259-268.
9Ignarro LJ, Buga GM, Wei LH, Bauer, et al. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation [J]. Proc Natl Acad Sci USA ,2001,98(7) : 4202-4208.
10Tailor A, Lefer DJ, Granger DN. HMG-CoA reductase inhibitor attenuates platelet adhesion in intestinal venules of hypercholesterolemic mice[J]. Am J Physiol Heart Circ Physiol, 2004, 286: H1402-H1407.
5Yeh R K, Chen J, Williams J L, Baluch M. Hundley T R, Rosenbaum R E,et al. NO donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more po tently than traditional NSAIDs: a general pharmacological property[J].? Biochem Pharmacol, 2004,67 : 2197-2205.
6Kashfi K, Borgo S, Williams J L, Chen J, Gao J. Glekas A, et al. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo[J]. J Pharmaeol Exp Tber, 2005,312 : 978-988.
7Williams J L,Nath N,Chen J, Hundley T R,Gao J,Kopelovich IJ,et al. Growth inhibition of human colon cancer cells by nitric oxide (NO) donating aspirin is associated with cyclooxygenase 2 induction and beta catenin/T cell factor signaling, nuclear factor kappal3,and NO synthase 2 inhibition: implications for chemoprevention[J].Cancer Res,2003,63:7613-7618.
8Spiegel A, H undley T R, Chen J, Gao J, Ouyang N, I.i u X, et al. NO donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT 29 human co Ion cancer cells[J]. Biochem Pharmacol, 2005,70 : 993-1000.
9Hundley T R, Rigas B. Nitric oxide donating aspirin inhibits colon cancer cell growth via mitogen actiwlted protein kinase ac tivation[J]. J Pharmacol Exp Ther,2006,316:25-34.
10Rigas B. The use of nitric oxide donating nonsteroidal anti in flammatory drugs in the chemoprevention of colorectal neopla sia[J]. Curr Opin Gastroentcrol,2007,23:55- 59.
